| Entry |
|
|---|
| Name |
Elexacaftor, ivacaftor and tezacaftor;
Trikafta (TN)
|
|---|
| Product |
|
|---|
| Component |
|
|---|
| Remark |
|
|---|
| Efficacy |
Cystic fibrosis treatment |
|---|
| Disease |
Cystic fibrosis (CFTR F508del mutation) [DS: H00218] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Brite |
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Cystic Fibrosis Agents
Conductance Regulator Potentiator
Elexacaftor/ Tezacaftor/ Ivacaftor
D11700 Elexacaftor, ivacaftor and tezacaftor
Target-based classification of drugs [BR:br08310]
Transporters
ABC transporters
ABCC subfamily
CFTR* [HSA_VAR:1080v1]
D11700 Elexacaftor, ivacaftor and tezacaftor <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11700
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11700
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11700
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
D11700
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
